AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Collection A extension spherical to develop their drug candidate AC01.
The financing was co-led by Novo Holdings, Pureos Bioventures, and Sound Bioventures. Present traders Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström additionally participated.
This funding will propel AnaCardio’s flagship drug candidate, AC01, via crucial scientific trials focusing on coronary heart failure with lowered ejection fraction (HFrEF).
AnaCardio’s CEO Patrik Strömberg commented, “This can be a landmark day for AnaCardio, the place we report a major financing spherical, welcome three distinguished new traders, and announce the optimistic end result of the primary examine with AC01 in sufferers. We now have the information and funding to speed up the additional scientific improvement of our first-in-class inotrope to enhance the lives of sufferers with coronary heart failure”.
AnaCardio was based in 2017 by Lars Lund, it’s a privately held Swedish scientific stage biopharmaceutical firm growing novel medication to deal with coronary heart failure. It was based based mostly on analysis from Karolinska Institutet exhibiting improved contractility of the center muscle via a novel and differentiated mechanism.
AC01, the corporate’s lead candidate, is a first-in-class oral ghrelin receptor agonist designed to boost cardiac contractility. Not like conventional inotropes, AC01 has proven potential to enhance coronary heart perform with out adversarial results generally related to present therapies, equivalent to tachycardia or hypotension.
The newly raised funds will help the completion of the part 1b/2a GOAL-HF1 examine, which features a 28-day cohort growth deliberate for early 2025. The examine’s earlier findings revealed AC01’s security and efficacy, demonstrating its capability to boost cardiac contractility whereas sustaining a beneficial security profile. These outcomes are hailed as a breakthrough in coronary heart failure therapies by AnaCardio.
“The examine outcomes exhibit that AC01 is a promising novel inotrope exhibiting indicators of elevated contractility with out adversarial results, equivalent to tachycardia, arrhythmias, ischemia or hypotension that are sometimes seen with standard inotropes when administered to sufferers with coronary heart failure. AC01 proved to be well-tolerated and confirmed convincing goal engagement meriting development to the subsequent improvement stage testing the drug for 28 days to ascertain proof-of-concept and allow progress to late-stage scientific improvement”, commented Professor Lars Lund, CSO and Founding father of AnaCardio.
Becoming a member of AnaCardio’s Board of Administrators are Johan Kördel (Sound Bioventures), Jørgen Søberg Petersen (Novo Holdings), and Veronica Gambillara Fonck (Pureos Bioventures). Moreover, Viktor Drvota, CEO of Karolinska Improvement, will exchange Per Aniansson, and Karin Hehenberger, Advisor at 3BFuture Well being, will transition to a board observer position.
“Coronary heart failure with lowered ejection fraction stays a significant unmet medical want, affecting thousands and thousands of lives worldwide. We’re thrilled to be a part of this groundbreaking initiative and proud to help the event of a brand new therapeutic possibility that has the potential to considerably enhance outcomes for sufferers going through this difficult situation,” stated Johan Kördel, Managing Companion, Sound Bioventures.